Treating PCOS With Semaglutide vs Active Lifestyle Intervention
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Girls with obesity and polycystic ovarian syndrome will receive either glucagon like
peptide-1 receptor agonist therapy or a dietary intervention for 12 weeks to decrease the
metabolic syndrome, in particular to lower hepatic fat and improve insulin sensitivity.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)